Dry eye disease (DED) is a complex condition that can result in significant vision complications. Analyzing systematic reviews of DED treatment contributes to selecting the most effective and safe drug. This review examines the efficacy of cyclosporine A and the generic Depores ophthalmic emulsion cyclosporine 0.05% (cyclosporine 0.05%, Deva Pharmaceuticals, Turkey) in the treatment of DED. A search for scientific information in PubMed, PubMed Central, The Cochrane Library, Google Scholar databases, and the Internet was carried out using keywords: dry eye disease, Cyclosporine A, Ikervis, Restasis, generic cyclosporine 0.05% ophthalmic emulsion, Depores. The literature cited in scientific articles was also reviewed. The analysis of scientific articles allowed us to conclude about the efficacy of the Restasis–Depores generic (cyclosporine 0.05%, Deva Pharmaceuticals, Turkey) for the treatment of patients with DED who have not yet had access to this treatment. Depores is now available in Georgia, bringing a novel treatment option to patients with severe DED. The study revealed a small number of clinical studies evaluating the efficacy and safety of generic cyclosporine 0.05% ophthalmic emulsion. Given the scarcity of research articles on this generic, it is necessary to study the results of its use in the treatment of DED in Georgia, which will help improve the quality of life with a diagnosis of dry eye.